Carna Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Carna Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth	24.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Carna Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSE:4572 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,440	-1,361	-973	-961	N/A
3/31/2024	1,579	-1,031	N/A	N/A	N/A
12/31/2023	1,625	-1,152	-1,688	-1,677	N/A
9/30/2023	1,002	-1,784	N/A	N/A	N/A
6/30/2023	1,047	-1,875	-2,306	-2,231	N/A
3/31/2023	1,058	-1,853	N/A	N/A	N/A
12/31/2022	1,386	-1,349	-834	-708	N/A
9/30/2022	2,476	-151	N/A	N/A	N/A
6/30/2022	2,426	-117	-52	12	N/A
3/31/2022	2,340	-263	N/A	N/A	N/A
12/31/2021	2,017	-534	-1,577	-1,536	N/A
9/30/2021	922	-1,640	N/A	N/A	N/A
6/30/2021	984	-1,490	-1,461	-1,401	N/A
3/31/2021	1,029	-1,213	N/A	N/A	N/A
12/31/2020	1,133	-1,111	-1,328	-1,260	N/A
9/30/2020	1,192	-934	N/A	N/A	N/A
6/30/2020	1,326	-764	1,144	1,200	N/A
3/31/2020	3,373	880	N/A	N/A	N/A
12/31/2019	3,207	828	1,436	1,477	N/A
9/30/2019	3,030	725	N/A	N/A	N/A
6/30/2019	2,815	474	-1,214	-1,178	N/A
3/31/2019	712	-1,252	N/A	N/A	N/A
12/31/2018	754	-1,210	-1,186	-1,128	N/A
9/30/2018	760	-1,051	N/A	N/A	N/A
6/30/2018	730	-910	-893	-834	N/A
3/31/2018	672	-813	N/A	N/A	N/A
12/31/2017	657	-737	N/A	-561	N/A
9/30/2017	713	-619	N/A	N/A	N/A
6/30/2017	695	-572	N/A	-510	N/A
3/31/2017	782	-396	N/A	N/A	N/A
12/31/2016	811	-289	N/A	-452	N/A
9/30/2016	873	-294	N/A	N/A	N/A
6/30/2016	877	-243	N/A	215	N/A
3/31/2016	1,460	351	N/A	N/A	N/A
12/31/2015	1,569	456	N/A	401	N/A
9/30/2015	1,428	116	N/A	N/A	N/A
6/30/2015	1,439	77	N/A	-269	N/A
3/31/2015	777	-641	N/A	N/A	N/A
12/31/2014	611	-846	N/A	-468	N/A
9/30/2014	671	-477	N/A	N/A	N/A
6/30/2014	736	-388	N/A	-303	N/A
3/31/2014	762	-322	N/A	N/A	N/A
12/31/2013	771	-282	N/A	-247	N/A
9/30/2013	700	-290	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4572's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if 4572's earnings are forecast to grow faster than the JP market

High Growth Earnings: Insufficient data to determine if 4572's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4572's revenue is forecast to grow faster than the JP market.

High Growth Revenue: Insufficient data to determine if 4572's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4572's Return on Equity is forecast to be high in 3 years time

Carna Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 40%

Consensus forecasts updated

Recent updates

Carna Biosciences, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

New major risk - Share price stability

Carna Biosciences, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: JP¥23.21 loss per share (vs JP¥32.77 loss in 1Q 2023)

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Carna Biosciences, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: JP¥68.57 loss per share (vs JP¥99.07 loss in FY 2022)

Carna Biosciences, Inc., Annual General Meeting, Mar 26, 2024

Carna Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Third quarter 2023 earnings released: JP¥20.13 loss per share (vs JP¥31.91 loss in 3Q 2022)

Carna Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: JP¥21.43 loss per share (vs JP¥25.25 loss in 2Q 2022)

Carna Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: JP¥32.77 loss per share (vs JP¥1.12 loss in 1Q 2022)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Full year 2022 earnings released: JP¥99.07 loss per share (vs JP¥42.06 loss in FY 2021)

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2023

Insufficient new directors

Carna Biosciences, Inc. to Report Q4, 2022 Results on Feb 10, 2023

Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Carna Biosciences, Inc. announced that it expects to receive ¥11.209315 million in funding from Cantor Fitzgerald & Co.

Third quarter 2022 earnings released: JP¥31.91 loss per share (vs JP¥31.70 loss in 3Q 2021)

Carna Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: JP¥25.25 loss per share (vs JP¥39.45 loss in 2Q 2021)

Carna Biosciences, Inc. to Report Q2, 2022 Results on Aug 05, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Carna Biosciences, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Carna Biosciences, Inc., Annual General Meeting, Mar 24, 2022

Consensus revenue estimates increase by 40%

Third quarter 2021 earnings released: JP¥31.70 loss per share (vs JP¥20.32 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥39.45 loss per share (vs JP¥17.31 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥23.06 loss per share (vs JP¥15.22 loss in 1Q 2020)

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Full year 2020 earnings released: JP¥90.33 loss per share (vs JP¥76.03 profit in FY 2019)

Revenue beats expectations, earnings disappoint

Carna Biosciences, Inc., Annual General Meeting, Mar 25, 2021

New 90-day high: JP¥1,433

Carna Biosciences, Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

New 90-day low: JP¥1,148

Third quarter 2020 earnings released: JP¥20.32 loss per share

New 90-day low: JP¥1,294

Carna Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low - JP¥1,371

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies